Advocacy intelligence hub — real-time data for patient organizations
Abhay Singh, MD MPH — PHASE2
M.D. Anderson Cancer Center — PHASE1, PHASE2
University of Illinois at Chicago — PHASE2
Halia Therapeutics, Inc. — PHASE2
Novartis Pharmaceuticals — PHASE2
Assistance Publique Hopitaux De Marseille — NA
AbbVie — PHASE3
Associazione Qol-one — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Travel grants
Travel Grants2
Rytelo
(IMETELSTAT SODIUM)Orphan drugGeron Corporation
12.1. Mechanism of Action Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the template region of the RNA component of human ...
Decitabine
(DECITABINE)Orphan drugBluePoint Laboratories
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Decitabine is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibi...
Lenalidomide
(LENALIDOMIDE)Orphan drugstandardTeva Pharmaceuticals, Inc.
Thalidomide Analog [EPC]
12.1 Mechanism of Action Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular act...
Inqovi
(CEDAZURIDINE AND DECITABINE)Orphan drugstandardTaiho Pharmaceutical Co., Ltd.
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Decitabine is a nucleoside metabolic inhibitor that is believed to exert its effects after phosphorylation and direct incorpo...
Grafapex
(TREOSULFAN)Orphan drugstandardMedexus Pharma, Inc.
Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review.
Decitabine, including its new oral formulation (decitabine-cedazuridine, DEC-C), is commonly used in AML and MDS, particularly in older or unfit patients. While its clinical efficacy and tolerability ...
Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome.
Myelodysplastic syndrome (MDS) represents a heterogeneous group of myeloid neoplasms, with approximately two-thirds identified as lower-risk MDS (LR-MDS). LR-MDS with thrombocytopenia is associated wi...
HIF-1α impairs NK cell differentiation-maturation and cytotoxicity in myelodysplastic syndrome via JAK1/STAT5/SOCS2 pathway.
Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid neoplasms characterized by treatment difficulties and a propensity to progress to acute myeloid leukemia. Impaired natural killer (NK...
Clonal Signatures of Telomere Biology Disorders.
In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecular fingerprint of the underlying pathophysiology. A specific clonal profile h...
TGFβ-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice.
Mutant SF3B1 (SF3B1mut) in hematopoietic stem/progenitor cells (HSPC) primarily affects erythropoiesis, resulting in myelodysplastic syndromes (MDS) with refractory macrocytic anemia and ring siderobl...
Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.
Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.
Hagop Kantarjian, MD, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
David A Sallman, MD, M.D
Moffitt Cancer Center
📍 TAMPA, FL
Minocher Battiwalla, MD, MD
National Institutes of Health- NHLBI
📍 NASHVILLE, TN
Corey Cutler, MD, MPH, F.N.P
Dana-Farber Cancer Institute
📍 PARK CITY, UT
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Esther Natalie Oliva, MD
CHU Amiens
📍 Amiens, MA